Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence

Abstract

Coronary artery disease (CAD) is highly prevalent in older adults, yet its management remains challenging. Treatment choices are made complex by the frailty burden of older patients, a high prevalence of comorbidities and body composition abnormalities (e.g., sarcopenia), the complexity of coronary anatomy, and the frequent presence of multivessel disease, as well as the coexistence of major ischemic and bleeding risk factors. Recent randomized clinical trials and epidemiological studies have provided new data on optimal management of complex patients with CAD. However, frail older adults are still underrepresented in the literature. This narrative review aims to highlight the importance of assessing frailty as an aid to guide therapeutic decision-making and tailor CAD management to the specific needs of older adults, taking into account age-related pharmacokinetic and pharmacodynamic changes, polypharmacy, and potential drug interactions. We also discuss gaps in the evidence and offer perspectives on how best in the future to optimize the global strategy of CAD management in older adults.

Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study

“…The RANGER study, with 616 patients aged 70 years old or more and 247 patients aged 80 years old or more, confirmed this finding with data obtained from a real-world setting. Considering that advanced age is associated with frailty and adverse outcomes, treatment must be individualised considering the comorbidities, risk factors, and haemodynamic variables [ 19 ].…”

2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

“…Moreover, combination therapy was associated with a significantly lower risk of therapy discontinuation or drug dose reduction (4.8% vs. 8.2%, p < 0.0001), while maintaining the same cardiovascular benefits (with the reduction trend – the absolute difference between group was –0.78%) [ 32 ]. Older people have a higher risk of intolerance, nonadherence, and discontinuation with HIS therapy [ 33 ]. In a subgroup analysis of the RACING study including patients with ASCVD aged ≥ 75 years, it was found that the use of combination therapy with a MIS with ezetimibe for 3 years was associated with a lower risk of intolerance compared to HIS monotherapy (2.3% vs. 7.2 %, p = 0.01), while maintaining the same cardiovascular benefits (HR = 0.87; 95% CI: 0.54–1.42) [ 34 ].…”

Coronary artery disease and transcatheter aortic valve implantation: diagnostic evaluation, management and indication for percutaneous revascularization

“…While it is clear that an acute coronary syndrome needs urgent revascularization of the culprit vessel, doubts still remains about the best timing for performing PCI in TAVI candidates with chronic coronary syndrome. As a fact, it is challenging to ascribe symptoms such as angina, syncope and dyspnea to the valvular heart disease or to the ischemic condition, especially in older adults; consequently, current ESC guidelines recommend PCI only in case of a severe (>70%) coronary artery stenosis in proximal segments (Class IIa) but do not advice about timing (3,11). Tarantini et al (6), analyzed pros and cons of performing PCI before, after or combined with TAVI (6).…”